Aytu BioPharma, Inc. Expected to Earn FY2023 Earnings of ($0.19) Per Share (NASDAQ:AYTU)

Aytu BioPharma, Inc. (NASDAQ:AYTUGet Rating) – Equities research analysts at HC Wainwright lifted their FY2023 EPS estimates for shares of Aytu BioPharma in a report issued on Wednesday, November 16th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings per share of ($0.19) for the year, up from their prior forecast of ($0.44). The consensus estimate for Aytu BioPharma’s current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Aytu BioPharma’s FY2024 earnings at $0.01 EPS.

Aytu BioPharma (NASDAQ:AYTUGet Rating) last posted its earnings results on Tuesday, September 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The company had revenue of $27.45 million for the quarter, compared to analyst estimates of $25.70 million. Aytu BioPharma had a negative return on equity of 47.20% and a negative net margin of 83.18%.

Aytu BioPharma Stock Performance

NASDAQ AYTU opened at $0.23 on Friday. The firm has a 50-day moving average of $0.18 and a 200-day moving average of $0.38. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.76 and a current ratio of 1.02. The stock has a market cap of $14.25 million, a PE ratio of -0.08 and a beta of -0.21. Aytu BioPharma has a 52-week low of $0.15 and a 52-week high of $2.40.

Institutional Trading of Aytu BioPharma

A number of hedge funds have recently modified their holdings of AYTU. Renaissance Technologies LLC lifted its stake in shares of Aytu BioPharma by 65.5% during the 3rd quarter. Renaissance Technologies LLC now owns 1,747,520 shares of the company’s stock worth $323,000 after buying an additional 691,738 shares during the last quarter. Prudential Financial Inc. lifted its stake in shares of Aytu BioPharma by 257.2% during the 3rd quarter. Prudential Financial Inc. now owns 145,550 shares of the company’s stock worth $27,000 after buying an additional 104,800 shares during the last quarter. Finally, Commonwealth Equity Services LLC raised its stake in Aytu BioPharma by 91.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 209,558 shares of the company’s stock worth $38,000 after purchasing an additional 99,859 shares in the last quarter. Institutional investors and hedge funds own 18.05% of the company’s stock.

About Aytu BioPharma

(Get Rating)

Aytu Biopharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old.

Read More

Earnings History and Estimates for Aytu BioPharma (NASDAQ:AYTU)

Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.